Grants for Public and State controlled institutions of higher education - Health

This funding opportunity provides financial support to organizations in New Jersey that offer training and employment services to individuals affected by the opioid crisis, helping them gain skills and secure jobs.

Funding Opportunity Description Developing medical countermeasures to protect civilians against intentional and accidental toxic chemical exposure that can lead to mass casualties is a major goal of the biodefense program at NIH. More specifically, this goal is executed by the Chemical Countermeasures Research Program (CCRP) at NIAID in partnership with several other ICs across the NIH (NIH Strategic Plan and Research Agenda for Medical Countermeasures Against Chemical Threats). NIAMS has been a critical and active partner in this trans-NIH effort since the CCRP’s inception in 2006. In order to broaden its research base and raise the awareness of the scientific community at large about the urgent need for effective countermeasures against chemical threats, the CCRP is encouraging its IC partners to issue IC-specific FOAs to further engage their respective research disciplines that are not currently engaged in the medical countermeasure research field. This initiative is a response to that request. The intent of the initiative is to encourage the NIAMS skin research community to contribute to the basic understanding of injuries caused by those toxic chemicals identified by the U.S. Department of Homeland Security as high consequence public health threats and to explore the local and systemic mechanisms of chemical wound development, healing, and long-term consequences. It is envisaged that such initiative will benefit both the national civilian defense program as well as the basic skin wound healing research at large. This initiative will emphasize understanding commonalities in the fundamental mechanisms of skin injuries caused by vesicants such as sulfur mustard, Lewisite, nitrogen mustard, phosgene oxime, and arsenicals, which may be different from thermal burn. The investigators are also encouraged to collaborate with researchers in tissues other than skin that are affected by the vesicants (e.g., eyes and lung) to find commonalities of injury mechanisms shared with skin. It is hoped that the fundamental knowledge gained would ultimately lead to the discovery and characterization of potential shared therapeutic targets (e.g., in signal transduction pathways and inflammation process) and the development of broad-spectrum medical countermeasures. This FOA is intended for investigators who are not currently supported under the CCRP’s CounterACT program but whose research interests are relevant to skin chemical injuries and to skin wound healing in general. It is assumed that the proposed project will represent a new direction for the applicant, which requires the applicant’s research lab to acquire new skills (e.g., handling toxic chemicals), gather new resources (e.g., establishing collaborative or contractual relationships with facilities certified to utilize restricted/controlled chemicals) and generate new preliminary data. Therefore, this FOA uses a planning mechanism (R34) to support such investigators to commence the preparatory steps toward this new line of study. This means that the applicants do not need to present preliminary data supporting the proposed study in concept, nor publication records and specific skills and proficiency in experimental execution in the chemical medical countermeasures field. However, the PD/PI should demonstrate prior experience in wound healing research and general knowledge relating to skin injury and healing. It is expected that a successful outcome of a proposed project is that the investigator has added within the laboratory (if needed) personnel with the skills and expertise to conduct studies in this area, established a working relationship with facilities certified for toxic chemicals (if needed), and gathered sufficient preliminary data to support a more comprehensive research project suitable under the other more translationally-focused CCRP FOAs.

This funding opportunity supports research projects that explore innovative combinations of radiation therapy and other treatments to improve cancer care, inviting applications from a diverse range of organizations, including universities, nonprofits, and for-profit entities.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support educational activities that encourage undergraduates from diverse backgrounds, including those from groups underrepresented in the biomedical workforce, to pursue further training and careers in the scientific, medical, ethical, social and/or legal areas of genomics research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences Courses for Skills Development This Genome Research Experiences to Attract Talented Undergraduates into the Genomic Field to Promote Diversity (GREAT) Program will support collaborative institutional partnerships that provide research education programs for undergraduates enrolled at minority-serving institutions (MSIs) or Institutional Development Award (IDeA)-eligible institutions. A partnership will include a MSI or IDeA-eligible institution, and one or more research-intensive institutions or organizations with a suitable research base for graduate-level training in scientific areas of interest to NHGRI.

This funding opportunity supports small-scale research projects that aim to improve the use of genomic information in clinical care, particularly for diverse and historically underrepresented populations.

This funding opportunity supports a variety of organizations in analyzing human kidney tissue samples to advance research in kidney disease and develop personalized treatment strategies.

This funding opportunity provides financial support to local governments and nonprofits in U.S. territories and freely associated states for infrastructure maintenance and resilience projects that enhance community development and disaster preparedness.

This Funding Opportunity Announcement (FOA) invites applications to develop and implement Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure.Research Objectives Utilizing the ACTC, the goal of this FOA is to invite research grant applications that provide clinical testing (Phases Ib-III) of promising pharmacological and/or non-pharmacological interventions for cognitive and neuropsychiatric symptoms in individuals with AD or other aging-related dementias across the spectrum from pre-symptomatic to more severe stages of disease. Working with the ACTC is a cooperative venture between the applicant, the NIA, and the ACTC network. NIA and the ACTC leadership will provide guidance to potential applicants. Potential applicants are strongly encouraged to contact NIA Scientific/Research Contacts (see Agency Contacts, Section VII) and the ACTC study team in order to discuss the feasibility of conducting the proposed trial through the ACTC infrastructure before considering an application. The ACTC infrastructure is welcoming of the following: Academic and industry applicants Pharmacological and non-pharmacological interventions Applications are encouraged that propose the following: Testing candidate therapeutic compounds against novel therapeutic targets Testing repurposed drugs derived from data-driven approaches, including candidates coming from NIA's translational bioinformatics FOA (PAR-17-032) Logistical guidance: Potential applicants undergo initial vetting of proposed study by the ACTC protocol evaluation committee and final review by the steering committee. Applicants should contact the ACTC study team at least 5 months prior to their desired NIA submission cycle. Contact details and more information may be found at actcinfo.org. Applications should anticipate using a centralized IRB. Applicants should be aware of the data and resource sharing requirements. The use of common contract language is strongly encouraged. Note, the ACTC infrastructure is not appropriate for: Single site clinical trials Routine Phase Ia first-in-human Clinical trials funded from this FOA will be implemented through the ACTC. The clinical trials approved for funding will develop their final protocols in conjunction with the ACTC. All ACTC sites will have the option to request participation and will be selected based on their capabilities specific to the individual protocols. Investigators are strongly encouraged to collect blood and other biosamples for future genomic and other 'omic' analyses aimed at interrogating treatment responsiveness and examining predictors of decline and progression. See Section VIII. Other Information for award authorities and regulations.

This grant provides funding for educational programs that help healthcare providers improve the identification and management of COVID-19 in pediatric patients with high-risk conditions.

The U.S. Embassy Libreville of the U.S. Department of State announces an open competition for organizations to submit applications to carry out a program to support Gabonese communities through modest grants that would positively impact communities. Program Objectives: Self-Help projects must foster community self-reliance. Self-Help activities must have community participation and contribution -- volunteer time and labor, donated land, equipment and materials -- and the U.S. contribution must be on a one-time basis only. Self-Help activities should have a significant impact, benefiting the greatest number of people possible. Projects that directly benefit a limited number of people are discouraged. Self-Help activities must help improve basic economic or social conditions at the local community or village level; Self-Help projects must also be viable and sustainable in terms of finance, personnel support (i.e. teachers for schoolrooms), and necessary expertise and services. Self-Help projects must also respect environmental norms for small projects. Self-Help activities must fall within the ability of the local community to implement. Activities that are too complex should be avoided.

This funding opportunity is designed to support higher education institutions, nonprofit organizations, and other eligible entities in establishing a coordination center to advance research on how our bodies sense and respond to internal signals, with a focus on improving mental health and overall wellness.

This funding opportunity supports research projects that improve the use of mammalian models, like organoids and tumoroids, to advance cancer research and develop effective treatments for patients.

This funding opportunity supports innovative research exploring how social isolation and loneliness contribute to suicide risk among older adults, particularly focusing on underrepresented communities and various social factors.

This funding opportunity provides financial support to early-career faculty at institutions with limited NIH funding to help them establish independent biomedical research programs and enhance student research experiences.

The Recovery Friendly Workplace Pilot Program, launched by the Maryland Department of Labor, aims to create a supportive environment for employees recovering from substance use disorders. The program encourages employers to adopt workplace policies that assist in employee recovery, provides stigma-reducing education, and facilitates research on recovery-friendly practices. It seeks to promote workplace well-being and recovery for employees and their families while fostering community awareness.

This funding opportunity is designed to enhance health services by engaging the private sector to improve family planning, maternal and child health, and control infectious diseases in various communities.

This grant provides funding to small businesses and startups that have previously received NSF Phase I awards, helping them advance their innovative research into market-ready products and services.

This funding opportunity supports U.S.-based institutions and organizations in developing innovative non-invasive optical imaging technologies for biological research and clinical applications, with a focus on improving imaging depth and resolution.

This funding opportunity provides financial and technical support to organizations working to improve HIV care and reduce transmission among low-income and vulnerable populations across the United States.

The National Center for Advancing Translational Sciences (NCATS) intends to publish aNotice of Funding Opportunity (NOFO) to solicit applications for research to advance the diagnosis, management, and treatment of rare diseases. Each Rare Diseases Clinical Research Consortium (RDCRC) will promote highly collaborative, multi-site, patient-centric, translational, and clinical research. It is strongly encouraged that the RDCRC study outcome measures include those that address unmet clinical trial readiness needs that will move the field of research forward from its current state. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in winter 2024, with an expected application due date in summer 2024. This NOFO will utilize the U54 activity code, which supports specialized centers through multi-project cooperative agreement awards to support research activities with substantial involvement from NIH program staff. Details of the planned NOFO are provided below.